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Abstract
 
Autoantibodies to histidyl–tRNA synthetase (HisRS) or to alanyl–, asparaginyl–, glycyl–, isoleu-
 
cyl–, or threonyl–tRNA synthetase occur in 
 
 
 
25% of patients with polymyositis or dermatomyo-
sitis. We tested the ability of several aminoacyl–tRNA synthetases to induce leukocyte migration.
 
HisRS induced CD4
 
 
 
 and CD8
 
 
 
 lymphocytes, interleukin (IL)-2–activated monocytes, and im-
mature dendritic cells (iDCs) to migrate, but not neutrophils, mature DCs, or unstimulated
 
monocytes. An NH
 
2
 
-terminal domain, 1–48 HisRS, was chemotactic for lymphocytes and acti-
vated monocytes, whereas a deletion mutant, HisRS-M, was inactive. HisRS selectively activated
CC chemokine receptor (CCR)5-transfected HEK-293 cells, inducing migration by interacting
with extracellular domain three. Furthermore, monoclonal anti-CCR5 blocked HisRS-induced
chemotaxis and conversely, HisRS blocked anti-CCR5 binding. Asparaginyl–tRNA synthetase
induced migration of lymphocytes, activated monocytes, iDCs, and CCR3-transfected HEK-293
cells. Seryl–tRNA synthetase induced migration of CCR3-transfected cells but not iDCs. Non-
autoantigenic aspartyl–tRNA and lysyl–tRNA synthetases were not chemotactic. Thus, autoanti-
genic aminoacyl–tRNA synthetases, perhaps liberated from damaged muscle cells, may perpetuate
the development of myositis by recruiting mononuclear cells that induce innate and adaptive
immune responses. Therefore, the selection of a self-molecule as a target for an autoantibody re-
sponse may be a consequence of the proinflammatory properties of the molecule itself.
Key words: myopathy • chemokine receptor • aminoacyl–tRNA synthetase • autoantibody • 
autoimmunity
 
Introduction
 
In the human idiopathic inflammatory myopathies, polymyo-
sitis, and dermatomyositis, patients experience debilitating
muscle weakness associated with an inflammatory cellular
infiltrate. Autoantibodies are common, and among them are
a number that are specific for myositis (1, 2). The most
common of these are directed against one or another of the
aminoacyl–tRNA synthetases. The most frequent specificity
 
(anti-Jo-1) is for histidyl–tRNA synthetase (HisRS),
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in 
 
 
 
15 to 25% of patients. A smaller percentage has autoan-
tibodies directed to alanyl–, asparaginyl–, glycyl–, isoleucyl–,
or threonyl–tRNA synthetases. Autoantibodies to both
tryptophanyl– and seryl–tRNA synthetases have been re-
ported in a few patients with systemic lupus erythematosus
or rheumatoid arthritis, but not myositis (3). The remaining
aminoacyl-tRNA synthetases have not been identified to be
the targets of autoantibodies in those or other illnesses, with
the exception that autoantibodies to LysRS occur in some
patients with anti-IleRS, presumably by epitope spreading
since both proteins are part of the multi-aminoacyl–tRNA
synthetase complex. The epitopes recognized by anti-Jo-1
are not identical in all patients (4), but the predominant an-
tigenic domain is the 
 
 
 
-helical NH
 
2
 
 terminus that is a
coiled-coil (5, 6). How these intracellular components of
protein translation participate in the development and pro-
gression of idiopathic myopathies is not understood.
The reasons for the generation of the autoantibody rep-
ertoire directed against a restricted set of autoantigens in
myositis or indeed in any autoimmune disease, have been
the object of extensive, but largely inconclusive specula-
tion. The explanations that postulate molecular mimicry of
a self component by a microorganism seem increasingly
unlikely (7, 8), and a generalized up-regulation of immu-
nity or down-regulation of tolerance lack the power to ex-
plain the limited repertory that is observed in human and
murine autoimmune disease. Recent observations by Dohl-
man on the frequent occurrence of coiled-coil struc-
tures in autoantigens (6, 9, 10), by Casciola-Rosen and
Rosen on the cleavability of autoantigens by caspases or
granzyme B and their localization in apoptotic blebs (11–
14), and by Utz, Anderson, van Venrroij, Tan, and Mam-
ula and their colleagues on modifications of proteins that
increase their antigenicity have pointed to the important or
even essential role of the biochemical structure of the au-
toantigens in determining their selection as targets (15–18).
It has been reported that human tyrosyl–tRNA syn-
thetase (TyrRS), not a known autoantigen, has both
chemoattractant and leukocyte activating activities when
proteolytically cleaved (19, 20). Proteolysis of TyrRS by
neutrophil elastase produces an NH
 
2
 
-terminal domain com-
posed of amino acids 1–364 and a COOH-terminal domain
composed of amino acids 365–528. The NH
 
2
 
-terminal do-
main of TyrRS binds to CXC chemokine receptor
(CXCR)1 and induces neutrophil chemotaxis, whereas the
COOH-terminal domain behaves like endothelial–mono-
cyte activating polypeptide II (EMAPII), inducing myelo-
peroxidase and TNF production as well as monocyte chemo-
taxis. In addition, functional homologues of EMAPII have
been identified in other aminoacyl–tRNA synthetases (21).
These findings suggested to us the possibility that pro-
inflammatory properties, specifically the chemoattractant
properties, of other aminoacyl–tRNA synthetases might
contribute to their choice as targets in myositis.
Both infiltrating lymphocytes and muscle cells in the
muscle tissue of patients express costimulatory markers (22)
and produce several proinflammatory cytokines. Several
reports have shown that elevated levels of selected chemo-
 
kines, e.g., CCL3 (macrophage inflammatory protein [MIP]-
1
 
 
 
), CCL4 (MIP-1
 
 
 
), CCL5 (regulated upon activation,
normal T cell expressed and secreted [RANTES]), and
CCL2 (monocyte chemoattractant protein [MCP]-1), are
found in myositis biopsies (23–27). Thus, chemoattract-
ants may contribute to the development or progression of
idiopathic inflammatory myopathies by regulating the in-
flux of inflammatory and immunoreactive cells into mus-
cle tissue.
We have compared the ability of two known myositis-
specific autoantigens, HisRS, and AsnRS, with three ami-
noacyl–tRNA synthetases not targeted in myositis, lysyl–
tRNA synthetase (LysRS), aspartyl–tRNA synthetase
(AspRS), and seryl–tRNA synthetase (SerRS), to act as
chemoattractants for various leukocytes.
 
Materials and Methods
 
Patient Specimens.
 
All specimens from patients were obtained
under protocols approved by the Institutional Review Boards of
the Clinical Center and the National Institute of Arthritis and
Musculoskeletal and Skin Diseases.
 
Reagents.
 
All chemokines and cytokines were obtained from
the National Institutes of Health cytokine repository. Recombi-
nant human HisRS, a deletion mutant of HisRS lacking the
amino-terminal 60 amino acids (HisRS-M) and 1–48 NH
 
2
 
-ter-
minal peptide (1–48 HisRS) were prepared as reported previously
(6). The decision to use this fragment was based upon the knowl-
edge that it contains the major autoantigenic epitope and is a
coiled-coil, and that granzyme B cleaves HisRS between residues
48 and 49 (unpublished data). Recombinant human AsnRS was
prepared essentially as described except with an NH
 
2
 
-terminal
His tag (28). The sonicated bacterial extract was loaded on a
TALON column (CLONTECH Laboratories, Inc.). After wash-
ing with 100 volumes of washing buffer (20 mM Tris-HCl, 1 M
NaCl, 5 mM MgCl
 
2
 
, EDTA free protease inhibitor tablets), the
synthetase was eluted with a buffer containing 20 mM Tris-HCl,
100 mM NaCl, 150 mM imidazole, and 10% glycerol and imida-
zole removed on PD10 columns (Amersham Biotech). The pro-
tein was then concentrated to 5 mg/ml in HEPES buffer, pH 7.2,
100 mM NaCl, 5 mM MgCl
 
2
 
, and 10% glycerol.
Human SerRS was expressed and purified as described previ-
ously and dialyzed against 20 mM HEPES buffer, pH 7.2, 100
mM NaCl, 5 mM MgCl
 
2
 
 and 10% glycerol (29). Recombinant
human LysRS (his-tagged) and AspRS (biotin-ubiquitin tagged)
were expressed in bacteria and purified by affinity chromatogra-
phy (unpublished data). All other reagents were purchased from
Sigma-Aldrich unless otherwise noted.
 
Cells.
 
Primary human leukocytes were isolated from fresh
normal donor apheresis packs under an approved human subjects
protocol as reported previously (30). In some studies, percoll pu-
rified lymphocytes or monocytes were cultured at 10
 
6
 
 cells/ml in
RPMI-1640 (Bio Whittaker) containing 10% fetal bovine serum
(HyClone) and 2 mM glutamine, 100 U/ml penicillin, and strep-
tomycin (Quality Biologicals) with 100 U/ml of rhuIL-2 for 3 d
in a 5% CO
 
2
 
 humidified tissue culture incubator. Lymphocyte
subsets were isolated using lymphocyte subset purification col-
umns as directed by the manufacturer (R&D Systems). HEK-293
cells were cultured in Dulbecco’s modified Eagle’s medium (Bio
Whittaker) containing 10% fetal bovine serum (HyClone) and 2
mM glutamine, 100 U/ml penicillin, and streptomycin (Quality 
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Biologicals). Parental HEK-293 cells were transfected with linear-
ized wild-type CCR5, CCR1, CCR3, or variant mammalian ex-
pression constructs by electroporation (31). Linearized chimeric
receptor constructs (32) were electroporated along with linearized
pcDNA3 (Invitrogen) in a 10:1 ratio. After selection in media
containing 800 
 
 
 
g/ml Geneticin (Life Technologies) for 2 wk,
cells were used for analysis.
Immature dendritic cells (iDCs) were generated from purified
human peripheral blood monocytes (
 
 
 
95%) which were incu-
bated at 10
 
6
 
 cells/ml in G4 medium (RPMI 1640, 10% FBS, 2
mM glutamine, 25 mM HEPES, 100 U/ml penicillin, 100 mg/
ml streptomycin, 50 ng/ml of rhGM-CSF, and 50 ng/ml of rhIL-
4) at 37
 
 
 
C in a humidified CO
 
2
 
 (5%) incubator (33). Half of the
medium was replaced on days 3 and 5 with fresh G4 medium.
On day 7, the cells in suspension were collected and used as
iDCs. As confirmed by flow cytometry analysis, iDCs were
CD1a
 
 
 
, CD14
 
 
 
, CD40
 
low
 
, CD83
 
 
 
, CD86
 
low
 
, HLA-DR
 
medium
 
.
Mature dendritic cells (DCs) were generated by treating the iDCs
for 48 h with 50 ng/ml of rhTNF-
 
 
 
.
 
Chemotaxis.
 
Cells were resuspended in binding media
(RPMI 1640 containing 1% bovine serum albumin, 25 mM
HEPES, pH 8.0) at 1–5 
 
  
 
10
 
6
 
 cells/ml. Chemokines diluted in
binding medium were placed in the lower wells of a chemotaxis
chamber (Neuroprobe). To observe chemotaxis of primary leu-
kocytes, five micrometer polycarbonate membranes were placed
over the chemokines. In the case of lymphocyte chemotaxis,
membranes were precoated with 50 
 
 
 
g/ml of fibronectin. To an-
alyze the response of HEK transfectants, a 10-
 
 
 
m polycarbonate
membrane precoated with 50 
 
 
 
g/ml rat tail collagen type1 (Col-
laborative Biomedical Products) at 37
 
 
 
C for 2 h was placed over
the chemoattractants. After the micro-chemotaxis chamber was
assembled, 50 
 
 
 
l of cells were placed in the upper wells. If recep-
tor blocking studies were being performed, 20 
 
 
 
g/ml of a recep-
tor blocking monoclonal antibody or an isotype control (45531;
R&D Systems) was added to the cell suspension 30 min before
the cells were added to the upper wells. The filled chemotaxis
chambers were incubated in a humidified CO
 
2
 
 incubator for 60
min for neutrophils, 90 min for monocytes, 3 h for lymphocytes,
or 5 h for HEK transfectants. After incubation the membranes
were removed from the chemotaxis chamber assembly followed
by gently removing cells from the upper side of the membrane.
The cells on the lower side of the membrane were stained using
Rapid Stain (Richard-Allen Scientific). The migrated cells were
counted by computer using the BIOQUANT 98 program
(R&M Biometrics). The number of cells migrating through the
membrane in a high power field was determined for medium
alone, chemokine-treated, and untreated cells. The average num-
ber of cells per high powered field (200
 
 
 
 magnification) was de-
termined for a given chemokine concentration and the standard
deviation reported in the error bars. Unpaired Student 
 
t
 
 tests
were performed between the media control and given chemo-
kine concentrations. Chemotactic index (C.I.) were calculated as
follows: ([average number of migrating cells in sample]/[average
number of cells in medium control]). C.I. was considered signifi-
cant if P 
 
  
 
0.001 compared with medium control. All experi-
ments were repeated at least three times.
 
Binding Studies.
 
Binding assays were performed in triplicate
by adding increasing amounts of unlabeled competitor and con-
stant 
 
125
 
I radiolabeled chemokine, 0.2 ng/assay (MIP 1 
 
 
 
-299;
New England Nuclear) to individual 1.5 ml microfuge tubes.
200 
 
 
 
l/samples of cells (2 
 
 
 
 10
 
6
 
 cells/ml) suspended in binding
media were added to the tubes and mixed by continuous rota-
tion at room temperature for 45 min. After incubation the cells
 
were centrifuged through a 10% sucrose/PBS cushion and the
cell-associated radioactivity was measured using a 1272 Wallac
gamma counter. A minimum of three independent binding as-
says were performed in triplicate for each cell type and radiola-
beled chemokine.
 
Immunohistochemistry for CCR3 and CCR5.
 
Immunohistochem-
istry was performed as described previously (22). Briefly, frozen
muscle tissues from eight myositis patients were acetone fixed and
blocked first with peroxidase blocking solution (Dako) and then
with serum containing 1:1 goat serum and pooled human serum.
The sections were incubated overnight at 4
 
 
 
C with a 1:50 dilu-
tion of primary monoclonal anti–human CCR5 or anti–human
CCR3 (R&D Systems) and with anti–mouse horseradish peroxi-
dase (HRP; Dako) for 1 h at room temperature. The tissues were
developed with DAB chromogen (Dako) and counterstained with
hematoxylin. Isotype matched (IgG2b) controls were used in
place of primary antibodies to confirm the specificity.
 
Fluorescence-activated Cell Sorting.
 
Peripheral blood mononu-
clear cells were separated from heparinized blood by ficoll den-
sity gradient. The cells were washed in ice cold PBS containing
1% human AB serum, 5% goat serum. PE-conjugated CD3, PE-
conjugated CD14, and FITC-conjugated anti-CCR5 clone
2D7 were purchased from BD Biosciences. FITC-conjugated
CXCR4 was purchased from R&D Systems. FACS
 
®
 
 analysis
was performed as described previously (34). Ligand-mediated
reduction of CCR5 monoclonal antibody binding was assayed
using antibodies specific to different domains of CCR5 (45523,
45531, 45549) (36). FITC-conjugated forms were purchased
from R&D Systems. CCR5/HEK cells were incubated with ei-
ther media, 1 
 
 
 
g/ml of CCL4, CCL5, or HisRS for 30 min,
followed by addition of saturating amounts of FITC-conjugated
monoclonal antibody.
 
Results
 
We began our studies by evaluating the ability of normal
primary human leukocytes isolated from apheresis samples
to migrate to either HisRS or AsnRS, known targets of
autoantibodies in myositis, and SerRS, LysRS, and Asp-
RS, which are not. In addition, we tested a recombinant
NH
 
2
 
-terminal deletion mutant of HisRS, HisRS-M,
and a synthetic peptide (1–48 HisRS). Neither primary
monocytes nor neutrophils responded chemotactically to
HisRS, HisRS-M, 1–48 HisRS, AsnRS, SerRS, AspRS,
or LysRS. However, percoll-isolated unfractionated lym-
phocytes and CD4
 
 
 
 and CD8
 
 
 
 lymphocyte subsets were
chemoattracted by HisRS and 1–48 HisRS. No leukocyte
subset was chemoattracted by HisRS-M. As can be seen in
Fig. 1, the maximum chemotactic activity for HisRS was
observed at 10 ng/ml (0.17 nM) for the unfractionated
lymphocytes (C.I. 
 
 
 
 2.2, P 
 
  
 
0.0001) and CD4
 
 
 
 lympho-
cytes (C.I. 
 
 
 
 2.7, P 
 
  
 
0.001). The maximal chemotactic
activity was at 50 ng/ml for CD8
 
 
 
 lymphocytes. The max-
imum chemotactic activity for 1–48 HisRS was obtained
with 100 ng/ml (18.9 nM) for unfractionated lymphocytes
(C.I. 
 
 
 
 2.3, P 
 
  
 
0.0001) and CD4
 
 
 
 lymphocytes (C.I. 
 
 
 
2.7, P 
 
  
 
0.0001). Again, there was a slight shift in the peak
dose for CD8
 
 
 
 lymphocytes. Thus, HisRS is a more po-
tent chemoattractant than the 1–48 HisRS peptide, but
both are efficacious. Unfractionated lymphocytes were not 
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chemoattracted to AsnRS (C.I. 
 
 
 
 1.4, P 
 
  
 
0.05, 
 
n
 
 
 
  
 
3) or
SerRS (C.I. 
 
 
 
 1.7, P 
 
 
 
 0.05, 
 
n 
 
  
 
3).
We investigated the effect of pertussis toxin on 1–48
HisRS-induced lymphocyte migration to determine if the
response was mediated by a G
 
 
 
i
 
 G-protein. Shown in Fig.
2, lymphocytes pretreated for 1 h with 
 
 
 
10 ng/ml of per-
tussis toxin failed to migrate (68%, P 
 
  
 
0.0001) in response
to 1–48 HisRS, suggesting that the response was largely
G
 
 
 
i
 
 G-protein mediated.
To clarify whether the effect of HisRS on migration was
due to chemotaxis or chemokinesis, we performed cross-
desensitization studies between CCL5 (RANTES) and
HisRS. The ability of lymphocytes to migrate in response
to CCL5 was greatly reduced, in a dose dependent manner,
when the cells were preexposed to HisRS (Table I, upper
panel). Conversely, the ability of lymphocytes to migrate to
HisRS was greatly reduced when cells were preexposed to
CCL5 (Table I, lower panel). Taken together, these data
indicate that the HisRS-induced migration is chemotactic
rather than chemokinetic, and furthermore that CCL5 and
Figure 1. Primary lymphocytes, CD4  and CD8  lymphocytes migrate to HisRS and 1–48 HRS but neutrophils do not. Recombinant HisRS
(HRS), a synthetic peptide corresponding to the first 48 amino acids of HisRS (1–48 HRS), or a deletion mutant form of HisRS that lacks the first 60
amino acids (M-HRS) were placed in the lower wells of a micro-Boyden chamber. The concentrations of various HisRS forms are shown on the x-axis
while the mean number of cells in a 200  field   standard deviation is shown on the y-axis. Binding medium indicates background, while CXCL-12
(SDF-1) or fMLP was used as a positive control. Each condition was performed in triplicate. Each assay was performed a minimum of three times. Un-
paired Student t tests were performed comparing the number of migrating cells in the binding medium vs. the number of migrating cells in individual
chemoattractant concentrations. * denotes a P value  0.0001.
Figure 2. HisRS-induced chemotaxis is inhibited by pertussis toxin.
Primary lymphocytes were incubated with increasing amounts of pertussis
toxin for 1 h before being added to the upper wells of a chemotaxis
chamber. Compared with binding media control, the HRS-induced mi-
gration was significantly reduced (unpaired Student t test, P   0.0001) at
10 ng/ml. Higher concentration of pertussis toxin begins to be toxic and
reduce spontaneous migration. Each condition was performed in tripli-
cate. Each assay was performed a minimum of three times.785 Howard et al.
HisRS share a common receptor. As CCL5 interacts with
CCR1, CCR3, and CCR5, this suggested that HisRS
might be acting on one or more of these receptors.
IL-2 treatment has been reported to enhance the expres-
sion of chemokine receptors by monocytes (35). Mono-
cytes treated for 3 d with 100 U/ml of human IL-2 did mi-
grate in response to HisRS (10 ng/ml). Pretreatment of
such IL-2–stimulated monocytes with HisRS or CCL4
(MIP-1 ), which uses predominantly CCR5, also inhib-
ited HisRS-induced chemotaxis (Fig. 3).
To identify the targeted receptor, we assayed the
chemotactic responses of a number of single chemokine re-
ceptor transfected HEK-293 cells. Neither CCR1 nor
CCR3 transfected cells responded to HisRS or 1–48
HisRS (data shown in Fig. 4 A). However, CCR5/HEK
transfectants did respond to HisRS in a dose-dependent
manner (Fig. 4 A). As observed for unfractionated and
CD4  lymphocytes, the maximum response was at 10 ng/
ml (C.I.   4.8, P   0.0001). Additionally, HOS/CD4/
CCR5 transfectants also migrated to HisRS (unpublished
data). As we already suspected that another CC receptor
that was less highly expressed on lymphocytes might be a
receptor for SerRS or AsnRS, we also tested them on a
number of CC chemokine transfected HEK cells. Both
SerRS and AsnRS induced CCR3-transfected cells to mi-
grate in a dose-dependent manner. The maximum re-
sponse for each was at 100 ng/ml (C.I.   2.0, P   0.0001;
Fig. 4 B).
The desensitizing effects of HisRS on CCL4 signal trans-
duction led us to determine whether HisRS and CCL4 are
competitive ligands for CCR5. Human IL-2–treated
monocytes showed 6761 cpm of specific CCL4 binding; a
250-fold molar excess of cold CCL4 completely blocked all
specific binding of radiolabeled CCL4. Even at a 2,000-
fold weight (250-fold molar) excess, HisRS was unable to
inhibit radiolabeled CCL4 binding. To explore the binding
further, we radiolabeled HisRS, but unfortunately radiola-
beled HisRS did not retain chemotactic activity (unpub-
lished data). This nonchemokine ligand also did not induce
calcium flux in lymphocytes, monocytes, or iDCs.
To circumvent these technical difficulties, we evaluated
chimeric receptors composed of extracellular domains of
CCR5 and CCR2 to determine if the receptor activation
domains for CCL2 (MCP1) and CCL5 (RANTES) corre-
sponded with those of HisRS (32). Earlier studies showed
that extracellular domain switching between CCR2 and
CCR5 could be used to map the extracellular domains
needed for HIV-1 infection. We used the same chimeric
receptor constructs to identify the extracellular domain(s)
of CCR5 that are essential to transmit a chemotactic signal
for HisRS. The first extracellular domain of CCR2 was li-
gated to the second, third and fourth extracellular domains
of CCR5, this chimera is known as 2555. The reciprocal
chimera is known as 5222. When the first two extracellu-
lar domains of CCR2 were ligated to the third and fourth
extracellular domains of CCR5, the chimera was known
as 2255.
As can be seen in Fig. 5, wild-type CCR5 transfected
into HEK cells is chemoattracted to 10 ng/ml or 100 ng/ml
of HisRS (C.I.   2.6) or 1–48 HisRS (C.I.   2.9), respec-
tively. CCL5, a known CCR5 ligand, induced significant
(P   0.0001) migration at 10 ng/ml. As expected, the HEK
cells transfected with wild-type CCR2 did not respond to
HisRS, 1–48 HisRS, or CCL5, but CCL2, a known
Table I. Cross Desensitization of Lymphocytes by HisRS and 
CCL5 (RANTES)
Lower
compartment
(ng/ml)
Upper compartment (ng/ml)
0 HRS 1.0 HRS 10 HRS 100
0 50.33   5.8 44.5   7.3 47.17   5.2 44.33   3
CCL5 1.0 51.5   7 46.33   7.2 50.17   3.1 50.33   6
CCL5 50 97.67   4.5 73.17   4.8 62.67   3.9 71.33   5.3
CCL5 1000 83.67   4.5 59.33   2.9 52.5   5.8 66.17   5.4
0 CCL5 1.0 CCL5 50 CCL5 1000
0 66.5   7.4 60.5   2.2 59.17   3.1 56.67   2.6
HRS 1.0 71.67   8.7 68   7.1 58.33   1.6 55.17   2.04
HRS 10 128.5   14.1 111   15.7 61.83   6.1 55.5   1.5
HRS 100 81.67   6.3 77.5   6.3 67.67   5.3 56.5   3.3
In the upper panel, cells were mixed with indicated concentrations of
HisRS before being added to the upper wells of a chemotaxis chamber. In
the lower panel, cells were mixed with the indicated concentrations of
CCL5 before being added to the upper wells of a chemotaxis chamber.
The mean number of cells per 200  field with a standard deviation is
reported. Each condition was performed in triplicate. Each assay was
performed a minimum of three times.
Figure 3. IL-2–cultured primary monocytes migrate to HisRS. Re-
combinant HisRS (HRS) was placed in the lower wells of a micro-Boy-
den chamber. The concentrations of HRS is shown on the x-axis while
the mean number of cells in a 200  field   standard deviation is shown
on the y-axis. Binding medium indicates background, while CCL4
(MIP1 ) was used as a positive control. IL-2–cultured monocytes were
tested for the ability of CCL4 and HRS to cross-desensitize each other.
Cells were mixed with 50 ng/ml of CCL4 or 10 ng/ml of HRS before
addition to the upper wells of the chemotaxis chamber. Each condition
was performed in triplicate. Each assay was performed a minimum of
three times.786 Select Aminoacyl-tRNA Synthetases Chemotactic for iDCs: Role in Myositis
CCR2 ligand, yielded a significant C.I. of 2.0 (P   0.001).
The 5222 construct did not transmit a HisRS, 1–48 HisRS,
or CCL5-specific chemotactic signal. However, a CCL2
(C.I.   1.8, P   0.001) response was observed. The 2555
construct showed the opposite pattern and did not transmit
a CCL2 chemotactic response but did respond to HisRS
(C.I.   1.9, P   0.001), 1–48 HisRS (C.I.   1.9, P  
0.001), and CCL5 (C.I.   4.2). As noted previously, the
2255 construct was able to respond to both CCR2 and
CCR5 ligands although the response was poor. Despite the
demonstrably low capacity to compete for the CCL5 bind-
ing sites on CCR5, HisRS (C.I.   2.5, P   0.0001) and
1–48 HisRS (C.I.  2.2, P   0.001) induced a substantial
chemotactic response in the 2255 construct expressing cells.
Epitope mapping studies indicated that a specific mono-
clonal antibody (clone 45531), which binds to the COOH-
Figure 4. (A) CCR5 transfected HEK/293 cells (CCR5/HEK) mi-
grate to HisRS. (B) CCR3 transfected HEK/293 cells (CCR3/HEK) mi-
grate to AsnRS and SerRS. Recombinant HisRS, SerRS, or AsnRS was
placed in the lower wells of a micro-Boyden chamber. The open circles
(CCR3) and open squares (CCR1) show the lack of chemotaxis of
CCR3 and CCR1 transfected HEK cells to HisRS. The concentrations
of are shown on the x-axis while the mean number of cells in a 200 
filed   standard deviation is shown on the y-axis. Each condition was
performed in triplicate. Each assay was performed a minimum of three
times. Unpaired Student t tests were performed comparing the number of
migrating cells in the binding media vs. the number of migrating cells in
individual chemoattractant concentrations. * denotes a P value  0.0001.
Figure 5. Migration of CCR5 and CCR2 chimeras to HisRS or 1–48
HRS. CCR5, CCR2, and chimeric constructs were expressed in HEK/
293 cells. Recombinant HisRS (HRS) or the 1–48 HRS peptide was
placed in the lower wells of a micro-Boyden chamber. The concentra-
tions of HRS is shown on the x-axis while the mean number of cells in a
200  field   standard deviation is shown on the y-axis. Each condition
was performed in triplicate. Each assay was performed a minimum of
three times. Unpaired Student t tests were performed comparing the
number of migrating cells in the binding media vs. the number of migrat-
ing cells in individual chemoattractant concentrations. * denotes a P value
 0.0001, ** denotes a P value of  0.001.787 Howard et al.
terminal portion of the second extracellular loop (also
know as the third extracellular domain), blocked both
CCL4 and CCL5-induced chemotaxis and HIV-1 infec-
tion (36). To determine if HisRS-induced chemotaxis
could also be blocked by this neutralizing antibody, we
pretreated cells with either an isotype match or 45531, then
placed the cells into the upper wells of a chemotaxis cham-
ber. As can be seen in Fig. 6 A, 45531 blocked HisRS-
induced chemotaxis while the isotype control did not. To
demonstrate that the reverse was also true, we incubated
either media, CCL5 or HisRS with CCR5/HEK for 30
min before addition of 45531 or a multidomain binding,
nonneutralizing monoclonal antibody 45523. Both anti-
bodies showed a large increase in relative fluorescence
compared with the isotype control (Fig. 6 B). The binding
of the multidomain binding antibody, 45523, was blocked
a greater extent by CCL5 (mean 70   3% SEM, n   3)
than by HisRS (mean 45.7   7.6% SEM, n   3). How-
ever, both CCL5 (mean 54.6   1.6% SEM, n   3) and
HisRS (mean 40.1   8.9% SEM, n   3) blocked 45531
binding. These studies, in combination with the binding
and cross desensitization data, suggest that HisRS is a
nonchemokine ligand for CCR5 that elicits a chemotactic
response by interacting with, at most, the third and fourth
extracellular domains of CCR5, but most likely the third
extracellular domain of CCR5.
The possibility that aminoacyl–tRNA synthetases inter-
act with receptors on antigen presenting cells with the ca-
pacity to initiate adaptive immune responses was next in-
vestigated. As immature, but not mature, DCs express
CCR5 and CCR3, we determined whether recombinant
HisRS, AsnRS, and SerRS were chemotactic for iDCs but
not mature DCs (37–39). As can be seen in Fig. 7, iDCs
demonstrated a chemotactic response to HisRS (C.I.  
1.7, P   0.0001). In addition, the known myositis autoan-
tigen, AsnRS, (C.I.   1.8, P   0.0001) induced iDCs to
migrate, but SerRS did not. These data suggest that HisRS
and AsnRS may be able to recruit CCR5- or CCR3-
expressing iDCs to damaged muscle. 1–48 HisRS did not
chemoattract iDCs, and mature DCs did not response
chemotactically to HisRS.
Immunohistochemical analysis was performed to deter-
mine if the infiltrating cells in muscle from myositis patients
have corresponding chemokine receptors. Earlier studies
showed that the mononuclear cells found in myositis tissue
were CD4  and CD8  lymphocytes, iDCs and monocytes
(22, 40). Several infiltrating mononuclear cells showed
CCR5 staining (Fig. 8 A). Similarly, CCR3 was present in
myositis infiltrates (Fig. 8 B). Some CCR5 staining was
also observed in the degenerating/regenerating muscle fi-
bers and in smooth muscle cells blood vessels of patients,
but not of normal volunteers. There was no staining when
Figure 6. (A) CCR5 neutralizing antibody blocks CCL4, CCL5, and
HisRS-induced CCR5/HEK migration. (B) CCL5 and HisRS (HRS)
block domain specific anti-CCR5 binding. CCR5/HEK cells were pre-
treated with either isotype control antibody, shown in hatched bars, or
neutralizing antibody 45531, shown in solid bars, then subjected to
chemotaxis. Pretreatment with 45531 significantly inhibited all induced
chemotaxis (* indicates P   0.0001 between sets designated by a bracket),
but did not inhibit spontaneous migration (*** indicates P   0.2). A repre-
sentative FACS® experiment of three is shown. Pretreatment with CCL5
blocked multidomain specific monoclonal antibody 45523 binding to a
greater extend than did HisRS (HRS). However, both CCL5 and HisRS
blocked extracellular loop 2 specific antibody 45531 binding, equally.
Figure 7. iDCs are chemoattracted to HisRS and AsnRS. Immature
DCs were generated from peripheral monocytes as described in Materials
and Methods. Recombinant HisRS (HRS) or recombinant AsnRS (NRS)
was placed in the lower wells of a micro-Boyden chamber. The concen-
trations are shown on the x-axis while the mean number of cells in a 200 
field   standard deviation is shown on the y-axis. Each condition was per-
formed in triplicate. Each assay was performed a minimum of three times.
Unpaired Student t tests were performed comparing the number of mi-
grating cells in the binding media vs. the number of migrating cells in indi-
vidual chemoattractant concentrations. * denotes a P value  0.0001.788 Select Aminoacyl-tRNA Synthetases Chemotactic for iDCs: Role in Myositis
the primary antibody was replaced with an isotype-
matched control (Fig. 8 C).
As these observations suggest that CCR5-expressing leu-
kocytes may play an important role in the pathogenesis of
myositis, we investigated the in vivo expression of this re-
ceptor. As CCR5  cells appeared to migrate into the in-
flamed muscle tissues in myositis patients, we investigated
the possibility that the expression of CCR5 by circulating
leukocytes was lower in anti-Jo-1 myositis patients (n   7)
than in unaffected individuals (n   8). We compared the
percentages of circulating CD3 CCR5 , CD14 CCR5 ,
CD3 CXCR4 , CD14 CXCR4  positive cells. As ex-
pected the percent of cells positive for CD3 and either
CCR5 or CXCR4 was low and not statistically different,
nor did the number of CD14 CXCR4  cells vary signifi-
cantly between the two groups. There was, however, a
34% decrease in the average number of CD14 CCR5 
cells in the anti-Jo-1–positive myositis patients in compari-
son to the average number observed in unaffected individ-
uals (P   0.035; Fig. 9).
Discussion
The studies reported here have identified HisRS, and to
a lesser extent an NH2-terminal peptide, 1–48 HisRS, and
AsnRS as aminoacyl–tRNA synthetases having proinflam-
matory functions. Specifically, HisRS is a nonchemokine
chemoattractant for CCR5-bearing cells that mediates its
chemotactic signal by interacting with at least the third and
fourth extracellular domains of the receptor, and AsnRS
induces CCR3-expressing cells to migrate. Both HisRS
and AsnRS chemoattract iDCs: cells known to express
these receptors on their surface. SerRS chemoattracts HEK
cells transfected with CCR3, but did not chemoattract
iDCs. Of these three proteins, two are targeted by autoan-
tibodies in myositis, and one, SerRS, has only been identi-
fied as an autoantigen in a few cases of systemic lupus
erythematosus or rheumatoid arthritis, never in myositis. It
is likely that the microenvironment of the tissue in which a
molecule is exposed to the immune system determines the
role that it will play in promulgating autoimmunity. Future
studies will have to test whether or not an interaction be-
tween an aminoacyl–tRNA synthetase and chemokine re-
ceptors is part of the immunopathogenesis of human exper-
imental myositis.
The potential of HisRS and AsnRS to recruit iDCs to
sites of muscle inflammation and the demonstrated presence
of inflammatory cells bearing CCR3, CCR5, and CD86 in
myositis muscle (22) suggests that these proteins themselves
Figure 8. Immunohistochem-
istry for CCR5 and CCR3.
Muscle biopsy slides from pa-
tients with myositis were stained
with anti–human CCR5 (A) or
anti–human CCR3 (B). Arrows
point to several CCR5 and
CCR3-positive mononuclear cells.
Isotype controls did not stain any
infiltrating mononuclear cells (C).
Original magnification: 340 .
Figure 9. Myositis patients have fewer CD14 CCR5  circulating leu-
kocytes. Peripheral blood was collected from unaffected individuals (n   8)
and anti-Jo-1–positive myositis patients (n   7). Peripheral mononuclear
cells were collected, stained for CD3, CD14, CCR5, or CXCR4 and
subjected to FACS® analysis. Median values with standard deviations are
plotted. The reduction observed between unaffected samples and affected
samples is statistically significant as determined by paired Student t test
P   0.036.789 Howard et al.
may participate in the initiation of an adaptive immune re-
sponse that leads to the production of autoantibodies. It has
been amply documented that antigens interacting with re-
ceptors on antigen presenting cells are processed tens of
thousands of times more effectively and are therefore more
immunogenic (41, 42). By engaging receptors on iDCs,
these aminoacyl–tRNA synthetases may be much more
likely to initiate T cell and B cell immune responses.
Studies by Blechynden and colleagues showed that in-
oculation of BALB/c and C57B/6 mice with naked DNA
constructs for expressing HisRS led to myositis localized
at the injection site (43), and there is precedent for che-
motactic activities encoded in naked DNA constructs en-
hancing the immune response (44). Thus, HisRS and As-
nRS, based on their chemotactic activity for iDCs, may
initiate a cascade of immune events, beginning with anti-
gen presentation to T lymphocytes and production of B
lymphocyte stimulating cytokines that result in the pro-
duction in autoantibodies in some patients. This suggests
that, in the framework of the “Danger Model of Immu-
nity” (45), autoimmunity, or at least autoantibodies, may
be a consequence of a danger signal borne by the target
autoantigen itself.
We report here that CCR5- and CCR3-bearing cells
are present in the affected tissues. TH1 T cells, particularly
CCR5  cells, are increased at sites of inflammation in idio-
pathic autoimmune disease like multiple sclerosis and rheu-
matoid arthritis (46–48). We have shown here that this is
also true in myositis. Earlier studies have similarly detected
the expression of CCR5 on smooth muscle cells found in
atherosclerotic plaques. Thus, a possible role for CCR5 in
the amplification of autoimmune inflammation is not un-
precedented. Although both genetic and environmental
factors are likely to play a role in at least some cases of myo-
sitis, the details remain largely speculative (49, 50). Based
on recent observations that CCR2 (51) as well as CCR5
and CCR3 expression are increased in affected tissues, the
role of potential allelic variants resulting in overexpression
of these chemokine receptors warrants study.
The expansion of previously selected lymphocytes in the
periphery is theorized to lead to a limited TCR repertoire
and increased autoreactive lymphocytes (52), but very little
is known about the specific T cells supporting the produc-
tion of myositis-specific autoantibodies or about the speci-
ficity of the cytotoxic T cells observed in the muscle (40,
53, 54). Indeed, very little is known about the T cells driv-
ing most autoantibody responses. The detection of TH1
cytokines in myositis tissue and the character of the im-
mune response to HisRS (55) strongly suggest that they
must participate. It is also possible that some of the amino-
acyl–tRNA synthetases are autoantigens for T cells in myo-
sitis, inducing cellular immunity without inducing accom-
panying humoral autoantibody production.
HisRS, AsnRS, and SerRS join several other amino-
acyl–tRNA synthetases that appear to have multiple physi-
ological roles. As noted in the introduction, several type II
aminoacyl-tRNA synthetases have now been demonstrated
to contain somewhere in their sequence leukocyte activat-
ing functions of various types (56), and fragments of TyrRS
and TrpRS have recently been reported to have cytokine-
like effects on angiogenesis (57, 58). Whether these extra-
curricular extracellular activities of aminoacyl–tRNA syn-
thetases are the accidental by–products of evolution or have
been selected for these roles remains to be discovered.
Finally, although the effects we have observed do not
fully delineate the immunological events leading to the
production of autoantibodies, they do extend the chain as
far as iDCs, thereby potentially connecting the chemotactic
activity to initiation of the adaptive immune response.
These studies suggest that self antigens that possess the ca-
pacity to interact with receptors on iDC, and not just au-
toantibodies, may play a direct role in initiation and pro-
mulgation autoimmune disease.
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